Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Amato, A. A.
Right arrow Articles by Kissel, J. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Amato, A. A.
Right arrow Articles by Kissel, J. T.
NEUROLOGY 1994;44:1516
© 1994 American Academy of Neurology

Inclusion body myositis

Treatment with intravenous immunoglobulin

A. A. Amato, MD, R. J. Barohn, MD, C. E. Jackson, MD, E. J. Pappert, MD, Z. Sahenk, MD and J. T. Kissel, MD

Department of Neurology (Drs. Amato and Pappert), Wilford Hall Medical Center, Lackland Air Force Base, TX; the Department of Neurology (Dr. Barohn), University of Texas Southwestern Medical Center, Dallas, TX; the Division of Neurology, Department of Medicine (Dr. Jackson), The University of Texas Health Science Center at San Antonio, San Antonio, TX; and the Department of Neurology (Drs. Sahenk and Kissel), The Ohio State University School of Medicine, Columbus, OH.

We report the results of nine patients with inclusion body myositis treated with intravenous immunoglobulin in an open-label uncontrolled study. None of our patients improved on objective manual muscle testing or functional disability scores. One patient developed mild neutropenia, complicating the intravenous immunoglobulin treatment. Our results do not exclude the possibility that intravenous immunoglobulin could be beneficial in some patients by slowing the rate of deterioration or perhaps stabilizing the disease. However, given the lack of objective improvement and high cost of treatment, we would not recommend intravenous immunoglobulin in the treatment of inclusion body myositis unless a blinded, controlled trial demonstrates clear benefit.

Address correspondence and reprint requests to Dr. Anthony A. Amato, WHMC/PSMN, 2200 Bergquist Dr, Ste 1, Lackland AFB, TX 78236-5300.

Received November 8, 1993. Accepted in final form February 7, 1994.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by AAN Enterprises, Inc.